Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sirolimus
Drug ID BADD_D02028
Description Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island).[A242412] It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent.[A13448] Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis.[A242417] Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer.[A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.[A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids.[A242412] In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis.[L39292] In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa).[L39267] Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis.[A242372]
Indications and Usage For the prophylaxis of organ rejection in patients receiving renal transplants.
Marketing Status Prescription; Discontinued
ATC Code L04AA10; S01XA23
DrugBank ID DB00877
KEGG ID D00753
MeSH ID D020123
PubChem ID 5284616
NDC Product Code 71052-202; 50268-718; 67877-746; 0008-1041; 16714-187; 59573-0004; 67877-748; 59762-1003; 59762-1002; 0008-1042; 73377-024; 60505-6197; 0008-1040; 42513-0013; 55111-654; 55486-1571; 51187-0010; 67877-747; 66689-347; 68382-520; 59762-1205; 55111-653; 42816-1042; 72969-067; 68254-1006; 73683-101; 68462-683; 0904-7147; 16714-188; 68084-915; 80803-153; 42816-1041; 57885-0014; 69238-1594; 42816-1040; 68462-682; 16714-189; 55500-0011; 59762-1001; 0008-1030; 68462-684; 56125-800; 13668-658; 65727-013; 65841-771
Synonyms Sirolimus | Rapamycin | I-2190A | I 2190A | I2190A | AY 22-989 | AY 22 989 | AY 22989 | Rapamune
Chemical Information
Molecular Formula C51H79NO13
CAS Registry Number 53123-88-9
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionErythroagglutinating phytohemagglutininP05088Not Available2246324; 2738100; 8880225; 8288727; 2515162; 6831033; 3871216; 1950737; 2548278; 2846698; 3262683; 7759599; 9869836; 2211719; 3131638; 2809200; 2540100; 9287244; 12082550; 7535569
Nephropathy toxicInterleukin-2P60568T616988591053; 7694398; 7592869; 7533090; 7542793; 7524531; 7520696
Nephropathy toxicNuclear receptor ROR-gammaP51449T253078591053; 7694398; 7592869; 7533090; 7542793; 7524531; 7520696
Nephropathy toxicCalcineurin subunit B type 1P63098Not Available8591053; 7694398; 7592869; 7533090; 7542793; 7524531; 7520696
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.002059%Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abscess11.01.08.001--Not Available
Acne23.02.01.0010.002059%Not Available
Alanine aminotransferase increased13.03.01.003--
Albuminuria20.02.01.001--Not Available
Alveolar proteinosis22.01.02.009--Not Available
Anaphylactic reaction24.06.03.006;
Anaphylactic shock10.01.07.002; Available
Anaphylactoid reaction24.06.03.007; Available
Aneurysm24.02.01.0010.000179%Not Available
Angioedema23.04.01.001; Available
Anorectal disorder07.03.01.001--Not Available
Anuria20.01.03.0020.000269%Not Available
Aphthous ulcer07.05.06.0020.002059%Not Available
Arterial thrombosis24.01.01.0020.000686%Not Available
Arthropathy15.01.01.0030.000686%Not Available
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; Available
The 1th Page    1 2 3 4 5    Next   Last    Total 15 Pages